By Lynne Peeples
Relebactam in combination with imipenem (IMI/REL; Merck) may fill a critical void in therapies effective against multidrug-resistant (MDR) infections, according to recent research.
On the basis of samples collected in the United States and Europe, IMI/REL showed significant activity—generally greater than 80% effectiveness—against MDR Pseudomonas aeruginosa and Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae.